Table 2 Improvement of AMS scores after testosterone-gel therapy. Stratification by age, BMI, and testosterone categories at baseline. The relative improvement is the difference between the pre- and post-treatment score divided by pre-treatment score as percents (%). Wilcoxon signed rank test was used to test differences of significance
From: Sensitivity as outcome measure of androgen replacement: the AMS scale
Total score | Psychological score | Somatic score | Sexual score | ||||||
|---|---|---|---|---|---|---|---|---|---|
n | % | p | % | P | % | p | % | p | |
All | 1670 | 30.7 (17.3) | < .0001 | 27.3 (22.4) | < .0001 | 30.5 (18.7) | < .0001 | 30.7 (20.6) | < .0001 |
Age | |||||||||
< 50 | 380 | 28.0 (18.4) | < .0001 | 23.8 (22.6) | < .0001 | 27.4 (20.0) | < .0001 | 28.3 (23.1) | < .0001 |
50–59 | 577 | 33.2 (17.6) | < .0001 | 29.4 (22.9) | < .0001 | 32.3 (19.2) | < .0001 | 34.4 (20.0) | < .0001 |
60+ | 713 | 30.1 (16.3) | < .0001 | 27.5 (21.6) | < .0001 | 30.6 (17.3) | < .0001 | 29.0 (19.1) | < .0001 |
BMI (kg/m2 | |||||||||
< 24.8 | 408 | 28.9 (17.5) | < .0001 | 25.0 (22.5) | < .0001 | 28.7 (18.4) | < .0001 | 28.8 (21.5) | < .0001 |
24.8 – 28.3 | 849 | 32.6 (16.3) | < .0001 | 29.4 (21.6) | < .0001 | 32.0 (18.1) | < .0001 | 33.1 (18.7) | < .0001 |
28.4+ | 413 | 28.4 (18.7) | < .0001 | 25.2 (23.5) | < .0001 | 28.9 (19.9) | < .0001 | 27.5 (22.6) | < .0001 |
Total testosterone (ng/ml) | |||||||||
< 1.81 | 424 | 31.0 (17.8) | < .0001 | 27.2 (22.5) | < .0001 | 31.1 (19.8) | < .0001 | 30.3 (21.8) | < .0001 |
1.81 – 2.99 | 832 | 31.3 (16.3) | < .0001 | 28.0 (21.8) | < .0001 | 30.8 (18.0) | < .0001 | 31.6 (18.8) | < .0001 |
3.00+ | 414 | 29.1 (18.6) | < .0001 | 26.1 (23.4) | < .0001 | 29.1 (18.9) | < .0001 | 28.2 (23.4) | < .0001 |